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the values measured in the GM maize–fed groups were 
compared with these equivalence ranges. Thirdly, the (sta-
tistical) power of these feeding studies with whole food/
feed was assessed and detectable toxicologically relevant 
group differences were derived. Linear mixed models 
(LMM) were applied, and standardized effect sizes (SES) 
were calculated in order to compare different parameters 
as well as to provide an overall picture of group and study 
differences at a glance. The comparison of the five feeding 
trials showed a clear study effect in the control data. It also 
showed inconsistency both in the frequency of statistically 
significant differences and in the difference values between 
control and test groups.
Keywords 90-day toxicity study · Genetically modified 
plants · Maize · Risk assessment · Historical control data · 
Linear mixed models · Standardized effect sizes · Statistical 
power · Consistency
Introduction
Feeding studies with whole food/feed to assess the safety 
of genetically modified crops—the EU−funded project 
GRACE
The safety of GM plants is a subject of intense political and 
societal debate, characterized by diverging positions in dif-
ferent EU Member States. For example, there is an ongoing 
debate regarding the necessity of 90-day animal feeding 
studies to assess the safety of genetically modified (GM) 
plants. In 2013, a new Commission Implementing Regula-
tion (European Commission 2013) came into force, which 
made 90-day feeding studies with whole food/feed manda-
tory in the frame of the safety assessment process of GM 
Abstract The data of four 90-day feeding trials and a 
1-year feeding trial with the genetically modified (GM) 
maize MON810 in Wistar Han RCC rats performed in 
the frame of EU–funded project GRACE were analysed. 
Firstly, the data obtained from the groups having been 
fed the non–GM maize diets were combined to estab-
lish a historical control data set for Wistar Han RCC rats 
at the animal housing facility (Slovak Medical University, 
Bratislava, Slovakia). The variability of all parameters is 
described, and the reference values and ranges have been 
derived. Secondly, the consistency of statistically signifi-
cant differences found in the five studies was analysed. In 
order to do so, the body weight development, organ weight, 
haematology and clinical biochemistry data were compared 
between the studies. Based on the historical control data, 
equivalence ranges for these parameters were defined, and 
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plants and derived products. This move was the result of a 
long-lasting discussion between the Member States and the 
European Commission aiming to incorporate the European 
Food Safety Authority (EFSA) Guidance for the GMO risk 
assessment into a legal text.
Before the Implementing Regulation became effec-
tive, 90-day animal feeding studies were only requested 
by EFSA in indicated cases (EFSA 2011a). Given the now 
mandatory but untargeted nature of the 90-day feeding tri-
als, the challenge was to determine the scientific value and 
limitations of such studies and how they should be inter-
preted within the risk assessment process. In this context, 
the EU-funded project GRACE comparatively evaluated 
the use of 90-day animal feeding trials, animal studies with 
an extended time frame as well as analytical, in vitro and 
in silico studies on GM maize in the GMO risk assessment 
process.
The performance of subchronic toxicity studies in form 
of 90-day feeding trials and of chronic toxicity studies 
in form of 1-year feeding trials using whole food or feed 
as test material is challenging. This is due to the fact that 
the available internationally accepted test guidelines such 
as the OECD Test Guidelines 408 (OECD 1998) and 452 
(OECD 2009) were originally developed to test the poten-
tial toxicity of chemicals.
There is a big difference between whole food or feed and 
chemicals as test material for this kind of studies. Chemi-
cals can be administered at dose levels that are much higher 
than those to which human beings are exposed. Such a test-
ing approach is not possible with whole food or feed, since 
the incorporation of high amounts of a crop to whole food 
or feed might lead to a nutritional imbalance. Therefore, 
when wanting to test the safety of GM crops, the OECD 
Test Guidelines used to test the potential toxicity of chemi-
cals need to be adapted to meet the constraints of whole 
food or feed testing.
Therefore, EFSA developed a guidance document/rec-
ommendations for the performance of feeding studies on 
whole food and feed in rodents based on the OECD Test 
Guidelines 408 and 453 (EFSA 2011b, 2013, 2014), but 
these documents do not provide prescriptive test protocols 
to carry out such experiments. Hence, four 90-day feeding 
trials and a 1-year feeding trial with whole GM and non-
GM plant material to validate and refine the suggested 
approaches were performed in the frame of the GRACE 
project (see below).
Specific challenges of feeding trials with whole food/
feed
From the point of view of the frequency with which param-
eters are assessed, two types of parameters are analysed in 
feeding studies. On the one hand, body weight and feed 
consumption are recorded once per week (“weight and feed 
consumption data”). On the other hand, organ weights, hae-
matology, clinical biochemistry, urinalysis as well as gross 
necropsy and histopathology parameters are determined 
once at the end of the study (“other parameters”). All these 
parameters are compared between the groups and tested 
with respect to relevant baseline values to identify any test 
substance– and dose–dependent toxic responses (Schmidt 
et al. 2016).
The first critical issue to be pointed out is that the dif-
ferent parameters are measured in different scales and in 
different units. The toxicological relevance of deviations 
differs from parameter to parameter. Nevertheless, for obvi-
ous reasons, all parameters are measured for the same fixed 
number of animals, as proposed, e.g. by OECD and EFSA. 
This approach results in a broad range of (possibly insuf-
ficient) statistical power values.
The second issue is that historical data (from the respec-
tive lab) are very important when assessing the toxicologi-
cal relevance of group differences measured in a feeding 
study. This is due to the fact that a natural variation among 
rats of an outbred strain such as the Wistar Han RCC strain 
used in all feeding trials performed in the course of the 
GRACE project does in fact exist. As stated, for example, 
in the OECD Test Guideline 452 (OECD 2009), historical 
control data may be valuable in the interpretation of the 
results of the study, e.g. in the case when there are indi-
cations that the data provided by the concurrent controls 
are substantially out of line when compared to recent data 
from control animals from the same test facility/colony. 
Historical control data, if evaluated, should be submitted 
from the same laboratory and relate to animals of the same 
age and strain generated during the 5 years preceding the 
study in question (OECD 2009). Unfortunately, no histori-
cal data regarding feeding trials with diets containing up to 
33 % maize were available at the animal housing facility 
of the Slovak Medical University in Bratislava, Slovakia, 
in which all feeding trials performed in the frame of the 
GRACE project were run. Consequently, minimum differ-
ences of toxicological relevance could not be set for a pro-
spective power analysis.
The third issue is related to the limited possibility of 
adding the GM crop to the feed at an inclusion rate that 
eventually will induce signs of toxicity and, thus, will 
allow to observe a dose–response relationship. In the 
frame of toxicity studies, chemicals are usually adminis-
tered at dose levels that are much higher than the probable 
human exposure levels, thereby leading to toxicologically 
relevant results in the high-dose groups. Such an approach 
is not always possible with whole food or feed, since high 
inclusion rates might result in nutritional imbalanced diets 
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(EFSA 2011b). EFSA (2014) suggested a 50 % incorpora-
tion rate as a reference value for a high dose of genetically 
modified maize in 90-day feeding trials in rodents, based 
on a study by Zhu et al. (2013) in Sprague–Dawley rats 
fed the glyphosate-resistant G2-aroA maize. At the present 
time, it remains unknown whether an incorporation rate of 
50 % maize will lead to a nutritional imbalance in long-
term feeding trials with a duration ≥1 year.
To handle the issue of statistical power in the case of 
whole food/feed studies, EFSA proposed to base the sam-
ple size on a pre-specified effect size defined in standard 
deviation (SD) units, thereby providing an example in 
which, based on data from previous toxicity tests and for 
all parameters, a difference of one SD or less is of little 
toxicological relevance (EFSA 2011b). EFSA also recom-
mends the use of fewer dose levels but more animals in the 
control and high-dose groups to maximize the power of the 
study. To handle the issue of toxicological relevance and 
to identify the range of the natural (non-positive) variabil-
ity of parameters, EFSA recommends to consider histori-
cal background data available in the actual testing facility 
and—if such data is not available—to include further refer-
ence groups.
Two different MON810 varieties with their corre-
sponding near–isogenic controls and four conventional 
maize varieties were used as plant material in the studies 
described here. The test approaches comprised the follow-
ing four 90-day feeding trials as well as a 1-year feeding 
trial:
• Study A: 90-day study with Monsanto MON810 maize
• Study B: 90-day study with Pioneer MON810 maize
• Study C: 1-year study with Monsanto MON810 maize
• Study D: Longitudinal and metabolomics 90-day study 
with Monsanto MON810 maize
• Study E: Longitudinal and metabolomics 90-day study 
with Pioneer MON810 maize.
The rat feeding trials A, B and C were conducted by 
taking into account the EFSA Guidance on conducting 
repeated−dose 90-day oral toxicity study in rodents on 
whole food/feed (EFSA 2011b) and the OECD Test Guide-
lines 408 and 452 (OECD 1998, 2009), and the results of 
these feeding trials have recently been published (Zeljen-
ková et al. 2014, 2016). The longitudinal and metabo-
lomics 90-day studies, as they were originally named by 
the GRACE consortium, refer to 90-day feeding trials per-
formed in the same way as were the studies A and B with 
one exception: In the studies D and E, blood and urine were 
collected from the tail vein of the animals at day 7 and after 
1, 2 and 3 months for immunological and metabolomics 
analyses, while in the studies A and B blood (no urine) was 
collected once at the end of the feeding trial.
Aims of the present study
In a first step, the data sets obtained in the feeding trials 
D and E, including the daily clinical observations, the oph-
thalmological findings, the body weight of the animals, the 
relative organ weights, the haematology and clinical bio-
chemistry parameters as well as the gross necropsy and his-
tological findings, are reported and discussed.
In a second step, the data sets of the feeding trials D and 
E together with those of the recently published studies A, B 
and C (Zeljenková et al. 2014, 2016) were used to address 
the specific issues described above. Specifically,
• “historical” control data of Wistar Han RCC rats fed 
whole food/feed diets containing 33 % non-GM maize 
for the animal housing facility at the Slovak Medical 
University (Bratislava, Slovakia) were compiled;
• the homogeneity of the historical control data was 
assessed;
• the toxicological relevance of any observed statisti-
cally significant differences between the control and 
test groups was analysed by assessing the consistency 
of such differences between GM and non-GM diet 
groups across the five studies and by comparing the data 
obtained with the GM-containing diets to the historical 
data;
• the (statistical) power of feeding studies with whole 
food/feed to detect toxicologically relevant group differ-
ences was assessed.
Materials and methods
Data from five 90-day feeding trials (studies A–E) per-
formed in the frame of the GRACE project were avail-
able (Table 1). A GM maize variety with the MON810 
event from Monsanto (St. Louis, MO, USA) was used in 
the studies A, C and D, while a GM maize variety with 
the MON810 event from DuPont Pioneer Hi-Bred Inter-
national (Johnston, IA, USA) was used in the studies B 
and E (Table 1). The European Commission requested the 
GRACE consortium to use the MON810 maize for the 
feeding trials, and the varieties used in the feeding trials 
are those being normally cultivated in Catalonia, Spain. 
In all studies, at least two GM groups (rats fed diets con-
taining 11 and 33 % GM maize) and a control group (rats 
fed a diet containing 33 % non-GM maize) were included. 
Group sizes were chosen to be 16 per sex in studies A and 
B according to an example in the EFSA Guidance Docu-
ment (EFSA 2011b), 20 per sex in study C according to the 
OECD Test Guideline 452 (OECD 2009), and 10 per sex 
in studies E and D according to the OECD Test Guideline 
408 (OECD 1998), see Table 1. The data of the feeding 
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trials A and B were analysed by Zeljenková et al. (2014; 
for details see Schmidt and Schmidtke 2014), those of the 
feeding trial C by Zeljenková et al. (2016; for details see 
Schmidt et al. 2015a) and those of the feeding trials D and 
E in this report (for details also see Schmidt et al. 2015b). 
The design of the 90-day studies A, B, D and E was the 
same with one exception: Blood and urine were collected 
at day 7 and after 1, 2 and 3 months for immunological and 
metabolomics analyses in the studies D and E, while blood, 
but no urine, was collected once at the end of the feeding 
trials A and B. For all trials, data quality and distribution 
checks and thereafter the above-mentioned individual anal-
yses were performed (as described in Schmidt et al. 2016). 
Raw data and statistical analysis reports of all studies are 
available at the CADIMA website. The open-access data-
base CADIMA is a non-profit internet portal aiming to 
increase the transparency and traceability of information 
being associated with the impact/risk assessment of plant 
genetic improvement technologies. Among others, it grants 
access to raw data generated by associated research activi-
ties (see www.cadima.info).
Maize varieties and diets
Studies A and B used maize material harvested in the 2012 
season in Pla de Foixa (Girona, Catalonia, Spain, 42°05′N, 
3°E). Studies D and E used the same batch of diets as stud-
ies A and B, respectively, but the diets were stored further 
on at −21 °C for 10 months. Study C used maize material 
from the 2013 harvest from the same region, but from dif-
ferent sites than the other studies. The maize varieties and 
the diets used are listed in Table 1.
Data structure
In all trials, the two treatment groups (11 % GM maize 
[11 % GMO] and 33 % GM maize [33 % GMO]) were 
compared to a control group (33 % non-GM control maize, 
[control]). Furthermore, additional groups fed conventional 
maize varieties were incorporated in trial A ([conven-
tional1] and [conventional2]), in trial B ([conventional3] 
and [conventional4]) and in trial C (again [conventional2]).
Body weight and feed consumption data: Each rat was 
weighed 14 times—starting on the first day of the trial and 
then proceeding on a weekly basis until the last weighing 
13 weeks later. Feed consumption was also determined 
once per week and reported as the total amount of feed 
consumed by two animals in one cage per week.
All other parameters: The following haematology 
parameters were determined: the white blood cell count 
(WBC), red blood cell count (RBC), haemoglobin con-
centration (HGB), haematocrit (HCT), mean cell volume 
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corpuscular haemoglobin concentration (MCHC), plate-
let count (PLT) and lymphocyte count (LYM) as well as 
the differential leukocyte count. The following clinical 
biochemistry parameters were measured: alkaline phos-
phatase (ALP), alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), albumin (ALB), total protein 
(TP), glucose (GLU), creatinine (CREA), urea (U), cho-
lesterol (CHOL), triglycerides (TRG), calcium (Ca), chlo-
ride (Cl), potassium (K), sodium (Na) and phosphorus 
(P). Moreover, except for trial C (since this was a 1-year 
feeding trial, rats were not sacrificed at t = 90 days), the 
weight of the kidneys, spleen, liver, adrenal glands, pan-
creas, lung, heart, thymus, testes, epididymides, uterus, 
ovaries and brain was recorded (the collated primary data 
are available on the website http://www.cadima.info). An 
overview of the data sets determined in all five studies is 
shown in Fig. 1.
In all five feeding trials, two animals per cage were 
held. According to the EFSA Guidance Document (EFSA 
2011b), the cage was defined as the experimental unit 
and means per cage were calculated for all parameters 
prior to the statistical analysis. All animals survived until 
t = 90 days, i.e. there were no missing data.
It has to be pointed out that statistical analyses were 
only performed on the quantitative parameters, i.e. the 
body weight, haematology, clinical biochemistry and rela-
tive organ weight data. Clinical findings were only, if at 
all, sporadically observed and, therefore, did not undergo 
any sort of statistical analysis (for details see Schmidt and 
Schmidtke 2014; Zeljenková et al. 2014, 2016; Schmidt 
et al. 2015a, b).
Individual study analyses
For each individual study, body weight and feed consump-
tion data were analysed by applying mixed models, sepa-
rately for each gender, and by using the restricted maxi-
mum likelihood (REML) algorithm with Toeplitz/AR(1) 
covariance structure. This approach considers the changes 
in both repeatedly measured parameters over all points in 
time and is a much more generalized model than nonlinear 
models or growth curves (Schmidt et al. 2016). The group 
(five/four/three levels) was considered a fixed factor. The 
factor week (time in weeks from the start of the experi-
ment) or day (time in days from the start of the experiment) 
was considered a quantitative fixed factor (repeated meas-
urements). For the resulting least square means, standard-
ized effect sizes with their 95 % confidence intervals were 
calculated for the comparisons of particular interest (mainly 
11 % GMO–control and 33 % GMO–control, in some stud-
ies also conventional–control) according to Nakagawa and 
Cuthill (2007). Moreover, a “classical” analysis of variance 
(ANOVA) was carried out, separately for each gender and 
each week. For the comparisons of particular interest (11 % 
GMO–control, 33 % GMO–control and conventional–con-
trol), post hoc Dunnett’s tests were performed after the 
ANOVA.
In the case of all other parameters, standardized effect 
sizes as well as their 95 % confidence intervals were calcu-
lated for the same group pairs and separately for each gen-
der (Festing 2014; Schmidt et al. 2016). All standardized 
effect size (SES) estimates are graphically shown, thereby 
displaying both statistical significance and presumptive 
decision thresholds for the toxicological assessment of 
each of the parameter comparison results (Fig. 2). Setting 
equivalence limits based on toxicological relevance is not 
easy and the subject of continued debate. In this paper, a 
working value for toxicological relevance is pragmatically 
set at equivalence limits of ±1.0 SD, as previously used 
in a simple example by EFSA (EFSA 2011b). It should 
therefore be kept in mind that future decisions on relevant 
equivalence limits may influence the equivalence results 
as presented in the current paper. The body weight as well 
as all other parameters are shown in the same graph (sepa-
rately for male and female rats), thereby forming an over-
all pattern and allowing the assessment of group compari-
sons at a glance. Again, an additional “classical” analysis 
with an ANOVA/post hoc Dunnett’s tests or nonparametric 
Kruskal–Wallis/Wilcoxon tests was carried out for each 
gender.
Fig. 1  Available data sets 
of the five feeding trials at 
t = 13 weeks. Study colours 
(A = blue, B = red, C = green, 
D = brown, E = purple) are 
applied in all graphs (colour 
figure online)
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Compilation of historical control data from the groups 
fed 33 % non‑GM maize‑containing diets
In the five feeding trials, two control and four other con-
ventional diets (all together named hereafter “non-GM 
diets”) were used (Table 2). The parameters measured in 
these groups were combined to compile historical non-
GM control data (point and interval estimates) for Wistar 
Han RCC rats fed a diet containing 33 % conventional 
maize in the animal housing facility at the Slovak Medi-
cal University (Bratislava, Slovakia). Reference statistics 
(mean, SD, minimum, maximum, percentiles: median, 5 
and 95 % percentiles) were calculated for the weight and 
laboratory parameters from all non-GM groups in the five 
feeding trials. To describe the variability, two measures 
were used: the coefficient of variation (relative SD, i.e. 
ratio of the SD to the mean) and the relative width of the 
90 % central interpercentile range (5–95 % percentile) to 
the mean.
The distribution of the non-GM diet-related data was 
graphically displayed in boxplots, separately for male and 
female animals and showing the median, the interquartile 
range = box length and extreme cases of individual vari-
ables in two categories, namely values between 1.5 and 3 
box lengths from the upper or lower edge of the box and 
cases with values more than 3 box lengths from the upper 
or lower edge of the box (shown in the statistical analy-
sis reports: Schmidt and Schmidtke 2014; Schmidt et al. 
2015a, b). All calculations and graphs were based on the 
values per cage (experimental unit).
Assessment of the homogeneity of the historical control 
data set
Firstly, to evaluate the reproducibility of the parameter 
measurements, an ANOVA was applied to compare the 
means of the individual studies. Secondly, to evaluate the 
magnitude of study–specific influences on the variance 
of the historical data set, a principal component analysis 
(PCA) followed by a cluster analysis (CA) was applied. 
The PCA was applied to combined male–female data to 
assess its suitability to separate expected gender differ-
ences (e.g. in the body and organ weights). The corre-
sponding values were converted into two principal com-
ponents, groupwise for body weight, haematology, clinical 
biochemistry and organ weight. Then, these components 
were grouped into five clusters. The number of compo-
nents and clusters were chosen both for practical and 
technical reasons. For PCA, varimax rotation with Kaiser 
normalization was used, and a hierarchical cluster analy-
sis was applied to form clusters based on their quadratic 
Euclidian distance. The resulting components were dis-
played graphically in a scatter plot.
Fig. 2  Simplified version of a graph allowing the visual assessment 
of statistical significance and toxicological relevance of group com-
parisons. The SES point estimate (circle) and the 95 % confidence 
limits (whiskers, bars showing confidence interval) illustrate the 
(standardized) effect size between two groups. The vertical black line 
indicates no statistically significant difference (zero difference), ver‑
tical dashed grey lines indicate toxicological relevance limits (here 
1.0 SD, according to the study design). If the confidence interval bars 
cross the zero line but not the grey dashed lines, i.e. they lie within 
the ±1.0 SD limits, there is evidence for no statistical significance 
as well as no toxicological relevance (case a). Two groups are sig-
nificantly different when the confidence interval bars do not cross the 
black vertical line (cases b, c). The effect size between two groups is 
supposed to be toxicologically relevant, when the confidence interval 
bars lie outside the ±1.0 limits (case c). Case b indicates statistical 
significance, but no clear toxicological relevance. Case d indicates 
no statistical significance, but no clear negation of toxicological rel-
evance (reproduced from Zeljenková et al. 2014)
Table 2  Number of values (cages) available in non-GM groups for the calculation of the historical control data ranges (78 values available for 
both male and female rats)
Study Non–GM varieties
DKC6666 DKC6815 PR32T16 PR33W82 PR32T83 SY–NEPAL Per study and sex
A 8 8 8 24
B 8 8 8 24
C 10 10 20
D 5 5
E 5 5
Per variety and sex 23 8 13 8 8 18 78
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Evaluation of the toxicological relevance of statistically 
significant differences
In its Scientific Opinion on statistical significance and bio-
logical relevance (EFSA 2011c), EFSA defined “The objec-
tive of carrying out an empirical study is usually to identify 
the existence of relevant biological effects at the population 
level using statistical tools to detect them. Therefore, the 
identification of statistical significance is only part of the 
evaluation of the biological relevance.”
As a basic principle, in each study, it was evaluated whether 
the observed statistically significant differences between the 
control and the test groups were in line with an effect pattern 
indicative of potential toxicity (e.g. liver toxicity).
To support the evaluation of the toxicological relevance of 
statistically significant differences identified in all five studies, 
the following approach was applied:
(i) a consistency check of differences across studies. A statis-
tically significant difference may be considered “consist-
ent” and might be an indicator of a toxicologically relevant 
(i.e. adverse) alteration if it is reproduced across studies.
(ii) a comparison of the values observed in the GM maize-fed 
groups with the historical control data set compiled from 
the non-GM groups of the five studies. A value outside of 
the historical control data range might be an indicator of a 
toxicologically relevant (i.e. adverse) alteration.
Consistency of statistically significant differences 
between GM and non‑GM diet groups
Firstly, in order to visually evaluate the consistency of the 
statistically significant differences, weight development 
curves as well as SES graphs of all five studies were com-
bined in one graph, allowing a direct visual comparison of 
differences observed in the individual studies.
Secondly, to evaluate the consistency of the frequen-
cies of statistically significant differences, total and rela-
tive numbers of such differences observed in haematology, 
clinical biochemistry and organ weight measurements of all 
five feeding trials were compared.
Thirdly, to evaluate the consistency of the difference val-
ues, the absolute differences between GM and non-GM diet 
groups were listed in form of tables for all studies, sepa-
rately for male and female animals. Statistically significant 
differences (positive or negative) were highlighted to easily 
compare their absolute values and their incidence.
Comparison of the values observed in the GM maize‑fed 
groups with the historical control data
The historical control data compiled from the non-GM 
groups of the five studies (Table 3) were used to set up 
simplified equivalence ranges (baselines) on the basis of 
the 1-SD approach. The mean and SD calculated for all 
non-GM (control and conventional) groups of the five stud-
ies were taken to set a lower equivalence limit (=mean–
SD) and an upper equivalence limit (=mean + SD). There-
after, it was checked whether the means of the individual 
parameters measured in the 11 % GMO- and 33 % GMO-
fed groups fell within or outside these limits.
Assessment of the statistical power of the studies
The power or sensitivity of a statistical test (here: of a com-
parison of the results from a GM with a control group) is 
the probability that the test correctly identifies an actu-
ally existing effect. “Actually existing” refers to the effect 
of toxicological relevance that is defined in advance of 
the study and thus co-determines the sample size. EFSA 
(2011b) described an example in which differences of one 
SD unit were considered of little toxicological relevance, 
resulting in a sample size of 16 animals per group and 
sex (i.e. 8 cages). Consequently, feeding studies designed 
according to this example aim to detect group effects of 
one SD value for all parameters measured.
On the basis of the historical control data compiled from 
the non-GM groups of the five studies, in a first approach 
without factoring the study effect, absolute values of effect 
sizes detectable with a power of 0.8 or 0.9 and sample sizes 
of (i) 10 animals per group and sex (OECD 2009), (ii) 16 
animals per group and sex (EFSA 2011b) or (iii) 20 ani-
mals per group and sex (OECD 1998) were determined for 
each single parameter. For these calculations, the experi-
mental unit is the cage with two animals.
For all analyses and graphs, the SAS Software, version 
9.4, from the SAS Institute Inc. (Cary, NC, USA) was used. 
SAS and all other SAS Institute Inc. product or service 
names are registered trademarks or trademarks of the SAS 
Institute Inc.
Results
90‑day feeding trials D and E
No signs of morbidity and mortality were observed 
throughout the 90-day feeding period, and the daily clini-
cal observations did not reveal any signs of functional defi-
cits in the feeding trials D and E. Furthermore, no ophthal-
mological alterations were visible in male and female rats 
fed the control, 11 % GMO and 33 % GMO diets in both 
trials. Body weight, relative organ weight as well as hae-
matology and clinical biochemistry data were analysed as 
described in the “Materials and methods, Individual study 
analyses” section and are shown for study D in Table 1 of 
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Table 3  Compilation of historical control data for male (A) and female (B) rats fed 33 % non−GM maize−containing diets in the GRACE pro-
ject 90-day feeding trials A, B, C, D and E
Parameter Count Meana Std Deviationa Mediana Minimuma Maximuma Percentile 05a Percentile 95a
A: Male rats
Body weight
 Week 0 [g] 78 149.9 6.5 150.2 137.6 167.8 138.9 161.5
 Week 1 [g] 78 198.1 7.8 197.3 180.9 217.1 186.2 213.3
 Week 2 [g] 78 240.1 9.1 239.3 218.9 262.0 225.6 258.6
 Week 3 [g] 78 276.4 11.9 276.3 249.3 303.5 256.2 297.1
 Week 4 [g] 78 303.5 14.9 303.3 265.3 335.8 280.3 330.2
 Week 5 [g] 78 328.4 15.4 327.3 286.2 360.5 305.6 357.3
 Week 6 [g] 78 348.4 17.1 346.7 304.0 384.7 322.1 379.1
 Week 7 [g] 78 364.6 18.4 362.6 320.8 403.3 334.8 397.5
 Week 8 [g] 78 377.6 20.4 377.1 326.7 422.3 347.0 411.8
 Week 9 [g] 78 391.1 20.7 390.5 344.7 436.0 357.0 424.9
 Week 10 [g] 78 401.3 21.2 401.1 356.4 451.4 366.5 437.7
 Week 11 [g] 78 411.9 22.7 412.3 363.6 466.8 378.0 453.3
 Week 12 [g] 78 419.7 22.4 416.6 372.1 474.8 387.2 465.2
 Week 13 [g] 78 422.9 23.5 417.8 377.2 488.5 388.9 465.9
Haematology
 WBC [103/µl] 78 10.14 2.88 9.28 5.10 18.55 6.21 15.42
 RBC [106/µl] 78 8.30 0.40 8.35 6.88 9.11 7.46 8.84
 HGB [g/dl] 78 16.09 0.83 16.20 12.00 17.25 14.23 16.96
 HCT [%] 78 45.98 2.25 46.13 38.10 49.30 41.24 48.87
 MCV [fl] 78 55.40 1.04 55.30 52.85 58.45 54.00 57.13
 MCH [pg] 78 19.40 0.62 19.40 16.45 20.50 18.37 20.33
 MCHC [g/dl] 78 35.02 0.97 34.95 29.30 36.50 33.94 36.31
 PLT [103/µl] 78 751.64 159.51 773.50 207.50 1041.50 369.98 933.45
 LYM [103/µl] 78 8.05 2.43 7.80 3.60 12.70 4.12 11.83
 Lymphocytes [%] 78 77.31 5.05 78.63 60.50 85.25 66.68 84.41
 Neutrophils [%] 78 17.51 4.91 16.00 8.75 31.00 11.50 28.39
 Monocytes [%] 78 3.47 1.34 3.50 1.00 9.50 1.86 5.75
 Eosinophils [%] 78 1.69 0.79 1.50 0.50 3.50 0.61 3.25
 Basophils [%] 78 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Clinical biochemistry
 ALP [µkat/l] 78 1.35 0.26 1.29 0.92 2.10 1.00 1.81
 ALT [µkat/l] 78 0.63 0.67 0.53 0.31 6.00 0.41 0.74
 AST [µkat/l] 78 1.44 0.79 1.19 0.78 6.20 0.83 2.50
 ALB [g/l] 78 34.35 3.17 33.68 27.80 41.55 29.84 39.82
 GLU [mmol/l] 78 8.63 2.14 8.57 4.90 13.75 5.27 12.68
 CREA [µmol/l] 78 43.31 6.61 42.93 29.80 58.35 32.95 55.98
 TP [g/l] 78 60.96 2.80 61.03 55.50 68.30 56.56 65.30
 U [mmol/l] 78 6.11 0.75 6.03 4.92 8.71 4.95 7.41
 CHOL [mmol/l] 78 2.29 0.29 2.28 1.78 3.20 1.86 2.91
 Ca [mmol/l] 78 2.57 0.20 2.54 2.15 3.03 2.18 2.95
 Cl [mmol/l] 78 108.03 6.64 107.00 100.00 150.00 102.23 116.55
 K (mmol/l) 78 4.83 0.57 4.78 3.85 7.20 4.02 5.81
 Na [mmol/l] 78 148.97 9.94 147.25 138.00 215.00 140.00 163.85
 P [mmol/l] 78 2.60 0.52 2.53 1.76 5.26 2.01 3.19
 TRG [mmol/l] 78 0.72 0.24 0.71 0.29 1.38 0.33 1.19
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Table 3  continued
Parameter Count Meana Std Deviationa Mediana Minimuma Maximuma Percentile 05a Percentile 95a
Organ weights
 Kidney (right) [%] 78 0.283 0.018 0.285 0.239 0.327 0.248 0.310
 Kidney (left) [%] 78 0.283 0.017 0.285 0.244 0.325 0.250 0.309
 Spleen [%] 78 0.185 0.017 0.184 0.155 0.228 0.159 0.220
 Liver [%] 78 2.214 0.169 2.180 2.026 2.968 2.037 2.581
 Adrenal gland (right) [%] 78 0.006 0.001 0.006 0.004 0.008 0.004 0.008
 Adrenal gland (left) [%] 78 0.007 0.001 0.006 0.005 0.012 0.006 0.008
 Lung [%] 78 0.330 0.033 0.326 0.270 0.434 0.286 0.388
 Heart [%] 78 0.230 0.012 0.228 0.208 0.257 0.214 0.257
 Thymus [%] 78 0.100 0.019 0.097 0.053 0.137 0.072 0.135
 Pancreas [%] 78 0.134 0.020 0.136 0.090 0.175 0.102 0.167
 Testis (right) [%] 78 0.468 0.037 0.465 0.403 0.566 0.411 0.549
 Testis (left) [%] 78 0.468 0.035 0.475 0.400 0.557 0.404 0.535
 Epididymis (right) [%] 78 0.152 0.012 0.152 0.129 0.179 0.132 0.176
 Epididymis (left) [%] 78 0.154 0.012 0.155 0.131 0.178 0.134 0.175
 Brain [%] 78 0.529 0.027 0.530 0.461 0.587 0.480 0.573
B: Female rats
Body weight
 Week 0 [g] 78 132.4 6.4 131.7 119.9 148.3 123.7 145.4
 Week 1 [g] 78 156.9 7.1 156.4 139.5 173.7 145.7 168.9
 Week 2 [g] 78 176.7 8.7 176.0 157.6 205.7 161.3 191.7
 Week 3 [g] 78 192.1 10.8 191.5 157.3 221.2 177.8 211.8
 Week 4 [g] 78 203.1 11.7 201.7 169.1 238.9 186.2 225.0
 Week 5 [g] 78 214.5 12.2 213.5 193.5 253.7 195.8 237.4
 Week 6 [g] 78 222.8 13.2 220.8 196.3 263.4 204.3 244.6
 Week 7 [g] 78 229.7 14.0 227.9 199.2 269.5 210.0 254.4
 Week 8 [g] 78 235.4 14.2 233.9 205.6 277.1 214.8 261.9
 Week 9 [g] 78 239.0 14.9 237.2 209.7 284.9 217.5 268.0
 Week 10 [g] 78 244.1 15.8 242.5 208.4 288.3 222.7 274.1
 Week 11 [g] 78 249.4 16.4 247.7 213.9 295.2 227.0 282.3
 Week 12 [g] 78 251.7 17.6 249.3 219.1 300.9 226.7 284.1
 Week 13 [g] 78 253.4 18.4 249.9 214.6 305.3 228.1 290.0
Haematology
 WBC [103/µl] 78 7.84 2.07 8.00 3.00 15.90 4.34 10.76
 RBC [106/µl] 78 7.67 0.29 7.64 7.15 8.38 7.20 8.29
 HGB [g/dl] 78 15.45 0.47 15.45 13.60 16.50 14.70 16.23
 HCT [%] 78 43.83 1.28 43.75 41.00 47.10 41.62 46.23
 MCV [fl] 78 57.19 1.15 57.30 54.40 60.00 55.04 59.35
 MCH [pg] 78 20.06 1.31 20.20 10.75 22.30 19.17 21.22
 MCHC [g/dl] 78 35.05 2.09 35.20 18.95 38.50 34.12 36.28
 PLT [103/µl] 78 783.61 135.85 787.75 294.00 998.50 487.55 989.55
 LYM [103/µl] 78 5.99 1.84 5.70 2.10 13.30 3.05 8.91
 Lymphocytes [%] 78 78.07 6.15 79.50 62.25 86.25 63.61 85.25
 Neutrophils [%] 78 17.56 5.75 16.38 8.50 33.50 10.34 30.69
 Monocytes [%] 78 2.68 0.86 2.75 1.00 5.25 1.50 4.66
 Eosinophils [%] 78 1.68 0.76 1.63 0.00 4.50 0.61 3.25
 Basophils [%] 78 0.04 0.09 0.00 0.00 0.25 0.00 0.25
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the Electronic Supplementary Material and for study E in 
Table 2 of the Electronic Supplementary Material. Moreo-
ver, all results (tables, graphs) are available in the Statisti-
cal Analysis Report at the CADIMA website www.cadima.
info.
No significant differences in body weight development 
and feed consumption were observed between groups (in 
both studies, in male and female rats, and by using linear 
mixed model analysis).
For all the haematology and clinical biochemistry 
parameters, SES were calculated. In this context, a statis-
tically significant difference means that the confidence 
interval of the SES to the control does not include the zero 
value, while “similar” means that the confidence interval of 
the SES to the control includes the zero value (Fig. 2).
The haematology parameters and the differential leuko-
cyte counts were similar between the groups fed GM maize 
and the control groups of male and female rats in both trials 
with the exceptions, as described below. In trial D (Elec-
tronic Supplementary Material, Table 1), MCV, MCH and 
the percentage of eosinophils were significantly increased 
in male rats fed the 11 % GMO diet when compared to the 
control group, while the percentage of neutrophils was sig-
nificantly decreased in male rats fed the 33 % GMO diet 
when compared to the control group. Furthermore, WBC 
were increased in female rats fed the 11 % GMO diet when 
compared to the control group, whereas WBC, MCHC 
and the number of lymphocytes per microlitre were sig-
nificantly increased in female rats fed the 33 % GMO diet 
when compared to the control group. In trial E (Electronic 
Table 3  continued
Parameter Count Meana Std Deviationa Mediana Minimuma Maximuma Percentile 05a Percentile 95a
Clinical biochemistry
 ALP [µkat/l] 78 0.59 0.10 0.58 0.33 0.85 0.43 0.76
 ALT [µkat/l] 78 0.48 0.14 0.47 0.19 1.13 0.26 0.69
 AST [µkat/l] 78 1.46 0.84 1.03 0.75 4.12 0.79 3.33
 ALB [g/l] 78 42.75 4.38 42.58 32.90 51.65 35.76 49.88
 GLU [mmol/l] 78 6.82 1.29 6.60 3.52 9.81 4.95 9.06
 CREA [µmol/l] 78 42.67 7.40 40.80 29.50 62.00 34.28 59.66
 TP [g/l] 78 68.62 5.47 69.38 56.45 80.45 57.42 76.64
 U [mmol/l] 78 5.62 0.72 5.55 4.55 7.65 4.59 6.90
 CHOL [mmol/l] 78 2.01 0.29 2.00 1.45 2.68 1.60 2.55
 Ca [mmol/l] 78 2.59 0.23 2.59 1.88 3.00 2.14 2.95
 Cl [mmol/l] 78 106.54 4.27 106.50 98.50 118.00 100.00 114.55
 K (mmol/l) 78 4.42 0.82 4.20 3.50 8.65 3.67 6.26
 Na [mmol/l] 78 148.16 5.37 148.00 137.50 161.00 139.00 156.30
 P [mmol/l] 78 2.33 0.41 2.38 1.55 3.60 1.62 2.94
 TRG [mmol/l] 78 0.52 0.16 0.53 0.16 0.99 0.27 0.75
Organ weights
 Kidney (right) [%] 78 0.316 0.019 0.314 0.278 0.358 0.284 0.350
 Kidney (left) [%] 78 0.316 0.020 0.315 0.265 0.366 0.276 0.349
 Spleen [%] 78 0.246 0.028 0.246 0.182 0.316 0.194 0.295
 Liver [%] 78 2.508 0.196 2.513 2.197 3.289 2.250 2.869
 Adrenal gland (right) [%] 78 0.014 0.002 0.014 0.008 0.019 0.010 0.017
 Adrenal gland (left) [%] 78 0.015 0.002 0.015 0.011 0.019 0.012 0.018
 Lung [%] 78 0.443 0.036 0.443 0.343 0.517 0.384 0.497
 Heart [%] 78 0.281 0.019 0.279 0.244 0.320 0.250 0.318
 Thymus [%] 78 0.131 0.018 0.129 0.100 0.174 0.109 0.165
 Pancreas [%] 78 0.183 0.028 0.181 0.110 0.281 0.144 0.231
 Uterus [%] 78 0.202 0.035 0.202 0.094 0.259 0.139 0.255
 Ovary (right) [%] 78 0.025 0.005 0.026 0.016 0.039 0.017 0.031
 Ovary (left) [%] 78 0.026 0.005 0.026 0.015 0.035 0.017 0.033
 Brain [%] 78 0.835 0.052 0.839 0.705 0.957 0.735 0.924
a Derived from cage values (average for 2 rats)
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Supplementary Material, Table 2), the percentage of neu-
trophils was significantly decreased in male rats fed the 
11 % GMO diet, while the percentage of lymphocytes was 
significantly increased and the percentage of neutrophils 
was significantly decreased in male rats fed the 33 % GMO 
diet when compared to the control group. Moreover, in 
female rats fed the 11 % GMO diet, the percentage of lym-
phocytes was significantly decreased and the percentage of 
neutrophils was increased when compared to the control 
group, whereas WBC and the percentage of monocytes 
were decreased in the 33 % GMO group if compared to the 
control group.
Clinical biochemistry parameters in both trials were 
similar between the groups fed GM maize and the con-
trol groups of male and female rats with the exceptions, 
as described below. In trial D (Electronic Supplementary 
Material, Table 1), ALP activity was significantly decreased 
in male rats fed the 11 % GMO diet, and U was signifi-
cantly decreased in the 33 % GMO group if compared to 
the corresponding control group. ALT, AST and U were 
significantly increased in female rats fed the 11 % GMO 
diet, while ALT, AST and TRG were significantly increased 
in female rats fed the 33 % GMO diet if compared to the 
corresponding control group. In trial E, no significant dif-
ferences between rats being fed the control diet and those 
fed the GMO diets were observed.
The relative weight of all organs was similar between 
the groups fed GM maize, and the control groups of male 
and female rats except in trial D the weight of the left kid-
ney were slightly lower in female rats fed the 11 % GMO 
diet than in the control rats (Electronic Supplementary 
Material, Table 1).
All parameters measured in the urine in both trials were 
similar with one exception: Osmolality was significantly 
increased in female rats fed the 33 % GMO diet when com-
pared to the control group.
No signs of morbidity and mortality were observed 
throughout the 90-day feeding period, and the daily clinical 
observations did not reveal any signs of functional deficits 
in feeding trials D and E. No ophthalmological alterations 
were visible in male and female rats fed the control, 11 % 
GMO and 33 % GMO diets in both trials. No macroscopi-
cally visible alterations were observed in male and female 
rats fed the control, 11 % GMO and 33 % GMO diets in 
both trials with the exception of a male rat (No. 32) fed the 
33 % GMO diet in trial E, in which the right seminal vesi-
cle and coagulating gland had a reduced size but without 
accompanying histopathological alterations. A low num-
ber of histological changes were observed in the control 
and 33 % GMO groups in trials D and E and mostly were 
inflammatory reactions (Electronic Supplementary Mate-
rial, Table 3). No pre-neoplastic and/or neoplastic lesions 
were observed. Since no treatment-related changes were 
observed between the control and high-dose groups, no fur-
ther tissue analyses were carried out.
Compilation of historical control data from groups fed 
33 % non‑GM maize‑containing diets
The 90-day body weight, haematology, clinical biochemis-
try as well as relative organ weight data from all non-GM 
groups of the five studies (i.e. those having been fed a diet 
containing either a control, i.e. near-isogenic, non-GM, or 
another conventional maize variety) were transferred to a 
meta-data file. As in the case of all analyses of previous 
GRACE feeding trials, those values were excluded from 
the analysis that showed distinct haemolysis or that were 
outside the dynamic range of the analyser, but no other sta-
tistical outliers or extreme values were removed from the 
data set (see Schmidt and Schmidtke 2014; Schmidt et al. 
2015a, b).
The compiled information on historical control values is 
shown in Table 3, in which the reference statistics (mean, 
median, SD, minimum, maximum, 5 and 95 % percentiles) 
for body weight per week, haematology and clinical bio-
chemistry parameters as well as relative organ weights of 
all non-GM groups in the five studies are listed.
Means and medians of the non-GM groups for 93 % of 
the parameters differed by less than 5 %, thereby indicating 
symmetric distributions (Table 4, columns 2 and 5). Only a 
few extreme values were observed (not shown).
The corresponding natural variation of the data was 
described by two parameters of variability (coefficient of 
variation and the relative width of the 90 % central inter-
percentile range), which are listed for each parameter in 
Table 4, columns 3–4 and, 6–7.
The coefficient of variation in body weight at the begin-
ning of the study was 4.3 % in males and 4.8 % in females, 
increasing over time up to 5.6 % in males and 7.3 % in 
females (week 13). The relative 90 % interpercentile range 
of the body weight measurements at the beginning of the 
study was 7.5 % of the mean in males and 8.2 % of the 
mean in females, also slightly increasing over time up to 
9.1 % of the mean in males and 12.2 % of the mean in 
females (week 13).
In the case of the haematology parameters, the coeffi-
cient of variation ranged between 2 and 45 %, whereas the 
90 % interpercentile interval varied between 3 and 78 % of 
the mean.
Clinical biochemistry parameters showed the highest 
variability: The coefficients of variation were about 5 to 
about 106 %, and the 90 % interpercentile intervals ranged 
from 4 to 86.7 % of the means. Relative organ weights had 
coefficients of variation of about 5–15 %, and 90 % inter-
percentile intervals ranged from 8 to 32 % of the means 
(Table 4).
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Table 4  Relative variability of historical control data: relative median−mean differences, coefficients of variation and relative widths of the 
95 % central interpercentile range (rats fed diets containing 33 % non−GM maize, data based on cage means [2 rats/cage])
Parameter Male Female
Mean–median Coeff. var. 90 % interval Mean–median Coeff. var. 90 % interval
Body weight
 Week 0 [g] 0.20 % 4.3 % 7.5 % −0.52 % 4.8 % 8.2 %
 Week 1 [g] −0.40 % 3.9 % 6.8 % −0.33 % 4.6 % 7.4 %
 Week 2 [g] −0.33 % 3.8 % 6.9 % −0.43 % 4.9 % 8.6 %
 Week 3 [g] −0.04 % 4.3 % 7.4 % −0.31 % 5.6 % 8.9 %
 Week 4 [g] −0.07 % 4.9 % 8.2 % −0.70 % 5.8 % 9.6 %
 Week 5 [g] −0.33 % 4.7 % 7.9 % −0.45 % 5.7 % 9.7 %
 Week 6 [g] −0.49 % 4.9 % 8.2 % −0.91 % 5.9 % 9.1 %
 Week 7 [g] −0.55 % 5.0 % 8.6 % −0.77 % 6.1 % 9.7 %
 Week 8 [g] −0.13 % 5.4 % 8.6 % −0.64 % 6.0 % 10.0 %
 Week 9 [g] −0.15 % 5.3 % 8.7 % −0.74 % 6.2 % 10.6 %
 Week 10 [g] −0.05 % 5.3 % 8.9 % −0.67 % 6.5 % 10.5 %
 Week 11 [g] 0.10 % 5.5 % 9.1 % −0.68 % 6.6 % 11.1 %
 Week 12 [g] −0.74 % 5.3 % 9.3 % −0.96 % 7.0 % 11.4 %
 Week 13 [g] −1.21 % 5.6 % 9.1 % −1.36 % 7.3 % 12.2 %
Haematology
 WBC [10³/µl] −8.54 % 28.4 % 45.4 % 2.00 % 26.4 % 40.9 %
 RBC [106/µl] 0.53 % 4.8 % 8.3 % −0.42 % 3.8 % 7.1 %
 HGB [g/dl] 0.68 % 5.1 % 8.5 % 0.03 % 3.0 % 5.0 %
 HCT [%] 0.32 % 4.9 % 8.3 % −0.19 % 2.9 % 5.3 %
 MCV [fl] −0.18 % 1.9 % 2.8 % 0.19 % 2.0 % 3.8 %
 MCH [pg] −0.02 % 3.2 % 5.1 % 0.71 % 6.5 % 5.1 %
 MCHC [g/dl] −0.20 % 2.8 % 3.4 % 0.42 % 6.0 % 3.1 %
 PLT [10³/µl] 2.91 % 21.2 % 37.5 % 0.53 % 17.3 % 32.0 %
 LYM [10³/µl] −3.12 % 30.2 % 47.9 % −4.90 % 30.6 % 48.8 %
 Lymphocytes [%] 1.70 % 6.5 % 11.5 % 1.84 % 7.9 % 13.9 %
 Neutrophils [%] −8.65 % 28.1 % 48.2 % −6.74 % 32.8 % 57.9 %
 Monocytes [%] 0.95 % 38.7 % 56.1 % 2.61 % 32.3 % 59.0 %
 Eosinophils [%] −11.50 % 46.8 % 77.8 % −3.07 % 45.2 % 78.7 %
 Basophils [%]
Clinical biochemistry
 ALP [µkat/l] −4.16 % 19.5 % 30.1 % −1.34 % 16.9 % 28.9 %
 ALT [µkat/l] −15.85 % 106.4 % 26.8 % −1.47 % 28.5 % 44.7 %
 AST [µkat/l] −17.27 % 54.9 % 57.9 % −29.40 % 57.6 % 86.9 %
 ALB [g/l] −1.97 % 9.2 % 14.5 % −0.42 % 10.2 % 16.5 %
 GLU [mmol/l] −0.69 % 24.8 % 43.0 % −3.24 % 18.9 % 30.1 %
 CREA [µmol/l] −0.88 % 15.3 % 26.6 % −4.37 % 17.4 % 29.7 %
 TP [g/l] 0.10 % 4.6 % 7.2 % 1.10 % 8.0 % 14.0 %
 U [mmol/l] −1.29 % 12.2 % 20.2 % −1.39 % 12.8 % 20.5 %
 CHOL [mmol/l] −0.27 % 12.7 % 22.9 % −0.40 % 14.2 % 23.8 %
 Ca [mmol/l] −1.09 % 7.8 % 15.0 % −0.04 % 8.9 % 15.7 %
 Cl [mmol/l] −0.96 % 6.1 % 6.6 % −0.04 % 4.0 % 6.8 %
 K (mmol/l) −1.11 % 11.8 % 18.5 % −5.01 % 18.6 % 29.3 %
 Na [mmol/l] −1.15 % 6.7 % 8.0 % −0.11 % 3.6 % 5.8 %
 P [mmol/l] −2.67 % 20.1 % 22.6 % 2.32 % 17.5 % 28.3 %
 TRG [mmol/l] −1.91 % 33.0 % 60.2 % 0.96 % 30.5 % 46.5 %
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Assessment of the homogeneity of the historical control 
data set
In 94 % of the ANOVAs applied to all parameters (to body 
weight per week, to haematology and clinical biochemis-
try parameters as well as to relative organ weights of male 
and female rats), the hypothesis that the five study means 
were equal was rejected, i.e. for these parameters the mean 
in at least one study was different from the mean of at least 
one other study. The hypothesis of equal study means could 
not be rejected for MCV, eosinophils, ALT and epididymis 
(right) in males as well as for basophils and adrenal (right 
and left) in females.
PCA followed by CA for body and relative organ 
weights showed a clear separation of male and female rats 
into two clusters (Fig. 3, top left and bottom right). Addi-
tionally, in the case of the body weight, but not in the case 
of the relative organ weights, studies A, B and C were 
grouped in one cluster, separated from a second cluster 
including studies D and E. Furthermore, the clinical bio-
chemistry parameters of studies A and B formed one clus-
ter, separated from a second cluster including the param-
eters of studies C, D and E (Fig. 3, bottom left). Regarding 
the haematology parameters, there was no discrimination 
between the studies (Fig. 3, top right).
Evaluation of the toxicological relevance of statistically 
significant differences
Consistency of statistically significant differences 
between GM and non‑GM diet groups
Visual evaluation of the consistency of body weight 
data The weight development in each study is displayed 
in Fig. 4 (control, 11 % GMO and 33 % GMO groups). The 
curves run parallel to each other, thus indicating a compara-
ble weight development in all studies. As already seen in the 
PCA graphs, all groups in studies D and E showed a slower 
body weight growth than in studies A, B and C.
Visual evaluation of the consistency of the other parame‑
ters The combined SES graphs of the five studies (both for 
11% GMO–control and 33 % GMO–control comparisons) 
are shown in Fig. 5: 37.5 % of haematology, 25.0 % of clini-
cal biochemistry parameters and 48.4 % of organ weights 
showed consistent difference values across the five studies. 
About 90 % of the SES confidence bars crossed the zero 
line (male comparison 11 % GMO–control: 89.0 %, male 
comparison 33 % GMO–control: 88.6 %, female compari-
son 11 % GMO–control: 92.3 %, female comparison 33 % 
GMO–control: 88.8 %), thereby indicating no statistically 
Table 4  continued
Parameter Male Female
Mean–median Coeff. var. 90 % interval Mean–median Coeff. var. 90 % interval
Organ weights
 Kidney (right) [%] 0.45 % 6.5 % 11.1 % −0.50 % 5.9 % 10.5 %
 Kidney (left) [%] 0.64 % 5.9 % 10.4 % −0.30 % 6.4 % 11.6 %
 Spleen [%] −0.61 % 9.1 % 16.7 % 0.04 % 11.5 % 20.4 %
 Liver [%] −1.53 % 7.7 % 12.3 % 0.20 % 7.8 % 12.3 %
 Adrenal gland (right) [%] 1.05 % 16.3 % 29.2 % 0.57 % 14.8 % 26.9 %
 Adrenal gland (left) [%] −2.66 % 14.4 % 16.5 % −0.44 % 11.2 % 20.1 %
 Lung [%] −1.24 % 10.0 % 15.3 % 0.07 % 8.1 % 12.8 %
 Heart [%] −0.90 % 5.3 % 9.2 % −0.95 % 6.8 % 12.1 %
 Thymus [%] −2.59 % 18.9 % 31.7 % −1.64 % 13.5 % 21.5 %
 Pancreas [%] 1.55 % 14.7 % 24.3 % −1.46 % 15.5 % 23.7 %
 Uterus [%] 0.38 % 17.5 % 28.9 %
 Ovary (right) [%] 2.74 % 18.6 % 29.2 %
 Ovary (left) [%] 2.85 % 19.2 % 31.9 %
 Testis (right) [%] −0.55 % 7.8 % 14.7 %
 Testis (left) [%] 1.61 % 7.4 % 14.0 %
 Epididymis (right) [%] 0.09 % 7.9 % 14.8 %
 Epididymis (left) [%] 0.31 % 7.8 % 13.3 %
 Brain [%] 0.04 % 5.0 % 8.8 % 0.51 % 6.3 % 11.3 %
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significant differences (see also Table 5). Single SES con-
fidence interval bars moved to the right or to the left; such 
shifts were replicated once or twice for less than 1 % of 
haematology parameters, about 2 % of clinical chemistry 
parameters and less than 5 % of organ weights, but no con-
fidence interval bar shift was reproduced in all five studies. 
Evaluation of the consistency of the numbers of statistically 
significant differences The total and relative numbers of 
statistically significant differences between the control and 
the test groups (based on SES estimates) in haematology, 
clinical biochemistry and organ weight measures (altogether 
45 for female parameters and 44 for male parameters) are 
shown in Table 5. Up to 20 % statistically significant differ-
ences were observed in the studies A and B, about 10 % in 
study D and below 5 % in the studies C and E. Therefore, 
the number of observed statistically significant differences 
was not consistent across the studies.
Evaluation of the consistency of the difference values The 
absolute 11 % GMO–control and 33 % GMO–control group 
differences for all parameters are shown in Table 6. Statis-
tically significant negative differences are highlighted in 
italics, while statistically significant positive differences 
are highlighted in bold. Differences were not replicated 
across the studies (i.e. the columns), and in the case of some 
parameters even opposite differences (italics/bold) were 
observed. The absolute values of statistically significant dif-
Fig. 3  Scatter plots of principal components scores for body weight (top left), haematology parameters (top right), clinical biochemistry param-
eters (bottom left) and relative organ weights (bottom right)
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ferences often deviated extremely from the differences in 
the other studies. Taken together, there was no single differ-
ence between a control and a GMO group that was consist-
ent across all five studies. 
Comparison of the values observed in GM maize‑fed 
groups with the historical control data baseline
The means and SD of the historical control data, as shown 
in Table 3, are included in columns 2–3 of Table 7, and 
the derived simplified equivalence ranges (mean + SD, 
mean − SD) are listed in columns 4–5. Additionally, the 
means of the GM group parameters of all five studies are 
shown, and mean values laying within the simplified equiv-
alence limits are highlighted in italics .
In male rats, 81.5 % of the parameters measured in the 
11 % GMO group and 81.8 % of the parameters measured 
in the 33 %GMO group were within the simplified equiva-
lence interval, whereas in female rats 77.9 % of the param-
eters measured in the 11 % GMO group and 82.3 % of the 
parameters measured in the 33 % GMO group were within 
the simplified equivalence interval. No dose–response rela-
tionship could be observed.
Moreover, 11.3 % of all parameters measured in study 
A, 7.8 % of all parameters measured in study B, 25.0 % of 
all parameters measured in study C, 26.9 % of all param-
eters measured in study D and 26.0 % of all parameters 
measured in study E were outside the equivalence limits.
Assessment of the statistical power of the studies
Table 8, part a, specifies the achievable statistical power to 
detect effect sizes of one SD (corresponds to √2 SD with 2 
animals/cage) with the given sample sizes proposed by sev-
eral internationally recognized test guidelines. Table 8, part 
b, specifies the relative effect sizes (in SD units) detectable 
with a power of 0.9 for the same given sample sizes.
Combining the relative effect sizes of Table 8, part b, and 
the historical control data, absolute and from a practical point 
of view relevant effects sizes were calculated. The values for 
given sample sizes of (i) 10 animals per group and sex (OECD 
2009b), (ii) 16 animals per group and sex (EFSA 2011 b) and 
(iii) 20 animals per group and sex (OECD 1998) in the case of 
two animals per cage are listed in Table 9. For the testing facil-
ity with the historical data background, these values represent 
the effect sizes that might be detected using statistical tools.
Fig. 4  Line graphs of weight development in male and female animals from the control, 11 % GMO and 33 % GMO groups in the studies A–E
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Fig. 5  a Combined SES graphs 
for studies A-E, (left: 11 % 
GMO—control, right: 33 % 
GMO—control), haematology 
parameters in male (top) and 
female rats (bottom); b com-
bined SES graphs for studies 
A-E, (left: 11 % GMO—con-
trol, right: 33 % GMO—con-
trol), clinical biochemistry 
parameters in male (top) and 
female rats (bottom); c com-
bined SES graphs for studies 
A-E, (left: 11 % GMO—con-
trol, right: 33 % GMO—con-
trol), body weight and relative 
organ weights of male (top) and 
female rats (bottom)
(a)
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Fig. 5  continued
1994 Arch Toxicol (2017) 91:1977–2006
1 3
Fig. 5  continued
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Discussion
90‑day feeding trials D and E
The feeding trials D and E were performed in parallel (i.e. 
all experimental conditions were strictly the same), while 
the studies A, B and C were performed at different points 
in time than the studies D and E in the same animal hous-
ing facility. Therefore, when discussing the relevance of 
statistically significant differences regarding a particular 
parameter between the control and the GMO-fed rats in the 
feeding studies D and E, it was considered pertinent to only 
compare the outcome of these two studies among them-
selves and not to include observations on alterations of the 
particular parameter in the feeding trials A, B and C.
There were no statistically significant differences 
between the mean body weights of the three experimental 
groups at any point in time of the feeding trials D and E in 
the case of male as well as female rats. Regarding the hae-
matology parameters, three out of 14 parameters in male 
rats fed the 11 % GMO diet and one out of 14 parameters 
in male rats fed the 33 % GMO diet were significantly dif-
ferent from the control male animals in trial D, while one 
out of 14 parameters in female rats fed the 11 % GMO diet 
and three out of 14 parameters in female rats fed the 33 % 
GMO diet were significantly different from the control 
female animals in trial D. In the case of study E, one out 
of 14 parameters in male rats fed the 11 % GMO diet and 
two out of 14 parameters in male rats fed the 33 % GMO 
diet were significantly different from the control male 
animals, whereas two out of 14 parameters in female rats 
fed the 11 % GMO diet and the 33 % GMO diet were sig-
nificantly different from the control female animals. It is 
important to note that the statistically significant changes in 
the haematology parameters in trial D were different from 
those observed in trial E with only one exception: The per-
centage of neutrophils decreased in male rats fed the 33 % 
GMO diet in both studies. In this context, the only haema-
tological alterations that showed a tentative dose–effect 
relationship were the decrease in the percentage of neutro-
phils in male rats as well as the increase in the MCHC and 
LYM in female rats in trial D and the decrease in WBC in 
female rats in trial E, whereby the values in all four cases 
were within or close to the value range of the control rats. 
Thus, the described alterations in the haematology param-
eters are not considered to be relevant from a toxicologi-
cal point of view. This conclusion is supported by the fact 
that after feeding the rats for 1 year with the diet contain-
ing 33 % MON810 maize no changes were observed in the 
four above-mentioned parameters in male and female rats 
(Zeljenková et al. 2016).
None of the clinical biochemistry parameters showed 
statistically significant differences in the three experimen-
tal groups of feeding trial E, while one out of 15 clinical 
biochemistry parameters in male rats and three out of 15 
clinical biochemistry parameters in female rats were signif-
icantly different when the data from control and GMO-fed 
rats in the feeding trial D were compared. The increased 
Table 5  Absolute and 
relative numbers of significant 
differences (based on SES 
estimates) in 11 % GMO−
control and 33 % GMO−
control group comparisons of 
the five feeding studies; total 
number of parameters: 45/44 
(male/female; haematology 
and clinical biochemistry 
parameters as well as relative 
organ weights)
Comparison Study
GM maize variety from Monsanto Pioneer
A C D B E
Absolute number of significant differences
11 % GMO–control
 Male 9 0 4 9 1
 Female 4 0 5 7 2
33 % GMO–control
 Male 13 0 2 7 2
 Female 2 1 6 12 2
Relative number of significant differences
11 % GMO–control
 Male 20.0 % 0.0 % 8.9 % 20.0 % 2.2 %
 Female 9.1 % 0.0 % 11.4 % 15.9 % 4.5 %
33 % GMO–control
 Male 28.9 % 0.0 % 4.4 % 15.6 % 4.4 %
 Female 4.5 % 3.3 % 13.6 % 27.3 % 4.5 %
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Table 6  Consistency of the difference values and significances (based on SES confidence intervals) across studies (statistically significant dif-
ferences are marked in bold: GMO group mean > control group mean, or in italics: GMO group mean < control group mean)
Parameter 11 % GMO–control 33 % GMO–control























 WBC [103/µl] −0.231 1.080 2.390 1.125 2.550 1.706 0.550 2.340 2.675 1.270
 RBC [106/µl] −0.047 −0.136 0.056 0.368 −0.140 0.260 0.018 −0.185 0.329 0.022
 HGB [g/dl] 0.138 −0.040 0.640 0.294 −0.300 0.406 0.030 0.160 0.213 0.170
 HCT [%] −0.750 −1.030 1.360 1.831 −1.030 0.869 0.350 −0.190 1.550 0.000
 MCV [fl] −0.663 −0.410 1.290 −0.225 −0.300 −0.750 0.360 1.080 −0.331 −0.110
 MCH [pg] 0.288 0.310 0.660 −0.456 0.000 −0.100 −0.010 0.660 −0.463 0.180
 MCHC [g/dl] 0.913 0.850 0.350 −0.688 0.160 0.288 −0.300 0.530 −0.650 0.380
 PLT [103/µl] 30.375 88.900 −73.100 5.938 −56.100 4.188 70.600 −46.400 24.063 9.800
 LYM [103/µl] −0.100 0.940 1.840 0.525 1.160 0.938 1.020 1.650 1.713 0.830
 Lymphocytes [%] −1.844 −0.200 1.200 0.594 5.800 −4.031 2.700 4.400 2.063 5.000
 Neutrophils [%] 1.094 −0.050 −2.800 0.719 −6.250 2.188 −2.200 −5.100 −0.438 −5.300
 Monocytes [%] 0.594 −0.500 0.050 −1.688 0.200 0.625 0.300 −0.100 −1.313 0.050
 Eosinophils [%] 0.188 0.750 1.550 0.375 0.250 1.219 −0.800 0.800 −0.281 0.250
 Basophils [%] 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
Clinical biochemistry
 ALP [µkat/l] 0.196 −0.084 −0.424 0.054 −0.238 0.128 −0.045 −0.266 0.162 −0.127
 ALT [µkat/l] 0.000 −0.013 −0.030 −0.015 0.024 −0.001 0.043 0.028 0.002 0.035
 AST [µkat/l] −0.055 0.203 0.199 0.043 0.097 0.139 0.430 0.449 0.064 0.043
 ALB [g/l] −0.769 0.900 0.610 0.244 0.160 −2.350 0.720 −0.900 −0.338 0.640
 GLU [mmol/l] 2.333 −0.197 0.217 −0.206 −0.314 2.355 −0.394 −0.173 −0.191 −0.877
 CREA [µmol/l] −3.213 −0.110 −0.710 0.488 3.140 −3.675 −1.220 −0.400 0.088 3.480
 TP [g/l] −4.475 1.420 0.340 0.244 −0.030 −6.756 0.720 −1.260 −0.663 0.170
 U [mmol/l] 0.056 −0.330 −0.042 0.583 0.167 0.358 −0.241 −0.542 0.831 −0.176
 CHOL [mmol/l] 0.550 −0.100 −0.077 −0.038 −0.325 0.508 −0.037 0.073 0.156 −0.249
 Ca [mmol/l] −0.034 −0.044 −0.021 0.348 −0.120 0.309 −0.058 0.042 0.331 −0.148
 Cl [mmol/l] 14.625 −1.600 0.400 −2.563 1.000 12.563 −2.200 −1.600 −1.813 −0.100
 K (mmol/l) 0.438 0.570 0.640 0.031 0.410 0.800 0.700 0.350 0.188 −0.150
 Na [mmol/l] 23.938 −0.400 −0.200 −5.411 0.800 18.563 −0.300 −0.400 −3.167 0.100
 P [mmol/l] 0.568 0.284 0.100 0.333 0.054 0.484 0.349 0.176 0.133 −0.156
 TRG [mmol/l] 0.264 0.082 −0.065 0.188 −0.056 0.336 0.008 0.067 0.124 0.014
Organ weights
 Kidney (right) [%] −0.001 −0.021 −0.001 −0.004 0.010 −0.015 −0.008 −0.003
 Kidney (left) [%] −0.001 −0.007 0.010 0.017 −0.002 −0.009 0.008 0.002
 Spleen [%] −0.011 0.002 −0.001 0.005 −0.010 0.013 −0.003 0.012
 Liver [%] 0.132 −0.053 −0.038 0.023 0.126 0.063 −0.001 −0.015
 Adrenal gland (right) [%] 0.000 0.001 0.000 0.001 0.000 0.000 0.000 0.000
 Adrenal gland (left) [%] 0.000 0.000 0.000 0.000 0.001 0.000 0.000 0.000
 Lung [%] −0.013 0.010 0.037 0.022 0.002 −0.013 0.020 0.003
 Heart [%] −0.010 0.006 0.008 −0.003 −0.003 0.002 0.007 0.008
 Thymus [%] 0.015 −0.005 0.001 0.002 0.013 −0.008 −0.015 −0.004
 Pancreas [%] −0.026 −0.002 −0.012 0.002 −0.029 0.013 −0.015 0.011
 Testis (right) [%] −0.024 0.008 0.029 0.017 −0.024 −0.022 −0.005 −0.005
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Table 6  continued
Parameter 11 % GMO–control 33 % GMO–control





















 Testis (left) [%] −0.020 0.002 0.039 0.010 −0.021 −0.026 −0.004 −0.011
 Epididymis (right) [%] 0.001 0.008 0.012 0.013 0.000 −0.002 0.013 0.001
 Epididymis (left) [%] 0.000 0.001 0.011 0.009 0.000 −0.007 −0.001 −0.001
 Brain [%] −0.003 0.019 0.023 0.006 −0.018 −0.008 0.004 0.003
B: Female rats
Haematology
 WBC [103/µl] −0.513 0.490 4.240 −1.194 −0.840 1.719 1.550 4.210 1.738 −1.690
 RBC [106/µl] −0.174 −0.442 0.139 0.343 −0.326 −0.139 −0.302 −0.100 0.312 −0.152
 HGB [g/dl] −0.163 −0.320 0.290 0.069 −0.180 −0.081 −0.160 0.070 0.131 0.050
 HCT [%] −0.488 −2.030 0.310 1.275 −1.760 −0.775 −2.010 −0.720 0.869 −1.240
 MCV [fl] 0.644 0.650 −0.620 −0.881 0.100 −0.019 −0.400 −0.160 −1.181 −0.510
 MCH [pg] 0.269 2.220 −0.030 −0.781 0.610 0.250 2.060 0.370 −0.650 0.470
 MCHC [g/dl] 0.044 3.660 0.390 −0.819 1.040 0.438 4.020 0.750 −0.400 1.150
 PLT [103/µl] 15.563 −42.900 −97.900 −29.125 30.100 −34.250 −43.700 −35.200 −78.313 −92.400
 LYM [103/µl] −0.494 0.450 1.500 −0.894 −0.660 1.294 1.110 2.150 1.700 −0.490
 Lymphocytes [%] −2.563 −0.600 −5.000 0.656 −8.600 −1.906 −1.100 0.800 1.313 1.200
 Neutrophils [%] 1.531 −0.400 4.550 −1.281 9.800 1.313 −0.400 −0.400 −2.938 0.200
 Monocytes [%] 0.656 0.100 −0.600 0.625 −1.500 0.750 −0.300 −0.700 1.500 −1.500
 Eosinophils [%] 0.375 0.950 1.050 −0.031 0.350 −0.156 1.800 0.250 0.125 0.150
 Basophils [%] 0.000 −0.050 0.000 0.000 −0.050 0.000 0.000 0.050 0.000 −0.050
Clinical biochemistry
 ALP [µkat/l] 0.268 0.070 −0.080 0.085 0.191 0.244 −0.035 0.041 0.103 0.078
 ALT [µkat/l] 0.093 0.035 0.193 0.036 0.108 0.011 0.019 0.340 0.078 −0.033
 AST [µkat/l] 0.121 0.382 1.532 0.028 0.151 0.224 0.769 1.865 0.184 −0.431
 ALB [g/l] 1.950 −0.910 0.740 −3.294 0.420 2.519 1.830 −0.360 −4.163 −0.450
 GLU [mmol/l] 0.640 0.675 0.092 0.263 −0.435 0.379 −0.519 −0.130 −0.386 −0.533
 CREA [µmol/l] 2.150 −1.330 −0.290 2.569 −1.450 2.663 1.560 −0.740 4.725 −0.940
 TP [g/l] 0.400 −1.290 0.950 −7.450 1.400 0.150 1.690 −0.070 −8.988 −0.770
 U [mmol/l] 0.288 0.432 0.471 0.723 −0.087 0.546 0.393 0.124 0.632 0.274
 CHOL [mmol/l] 0.149 0.250 −0.050 0.172 0.198 0.062 −0.005 −0.216 −0.084 −0.068
 Ca [mmol/l] 0.018 −0.006 0.019 0.308 0.022 −0.061 −0.001 0.030 0.175 −0.010
 Cl [mmol/l] 4.563 −1.500 −1.700 0.313 −1.000 −0.250 −1.700 −1.100 −0.625 1.000
 K (mmol/l) 0.138 −0.110 0.460 0.294 0.070 −0.106 0.350 1.120 −0.094 0.180
 Na [mmol/l] 6.938 −0.300 0.600 −0.375 0.800 0.688 −0.600 0.500 −4.750 0.700
 P [mmol/l] 0.151 −0.110 0.320 0.209 −0.086 −0.234 −0.028 0.546 −0.097 −0.028
 TRG [mmol/l] −0.074 −0.139 0.101 −0.085 −0.008 −0.137 −0.038 0.211 −0.160 0.009
Organ weights
 Kidney (right) [%] −0.005 −0.029 0.005 −0.004 0.005 −0.016 0.003 0.005
 Kidney (left) [%] 0.008 −0.018 −0.008 0.005 0.012 −0.009 −0.009 0.014
 Spleen [%] −0.006 0.017 −0.011 0.005 −0.006 0.004 −0.006 0.009
 Liver [%] 0.030 0.014 −0.006 0.022 0.028 0.086 0.083 −0.130
 Adrenal gland (right) [%] 0.001 0.001 0.000 −0.001 0.001 0.002 0.002 0.000
 Adrenal gland (left) [%] −0.001 0.000 0.001 0.001 0.001 0.001 0.001 0.001
 Lung [%] −0.007 −0.014 0.000 0.008 −0.019 0.004 0.029 0.012
 Heart [%] 0.000 0.007 0.007 0.003 −0.005 0.001 0.015 0.008
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ALT and AST activity in female rats were not accompa-
nied by changes in the ALB and TP levels and/or by histo-
pathological alterations in the liver and were not observed 
in female rats in the feeding trial E. An increased U level 
was observed in female rats fed the 11 % GMO diet but 
not the 33 % GMO diet, and the increased TRG level in the 
female rats fed the 33 % GMO diet was not accompanied 
by a lipid accumulation in any of the histologically exam-
ined organs and was not observed in trial E. Based on the 
above-mentioned observations, the described alterations in 
the clinical biochemistry parameters are not considered to 
be toxicologically relevant and are not related to the diets 
supplemented with the MON810 maize varieties.
A low number of histological changes, mostly inflam-
matory reactions and no pre-neoplastic/neoplastic lesions, 
were observed in the control and 33 % GMO groups in tri-
als D and E, which is in accordance with the findings in the 
previously published 90-day feeding trials A and B (Zeljen-
ková et al. 2014).
Compilation of historical control data from groups fed 
33 % non‑GM maize‑containing diets
In this study, historical control data regarding body weight 
development, haematology and clinical biochemistry 
parameters as well as relative organ weights of male and 
female Wistar Han RCC rats having been fed a diet con-
taining 33 % non-GM maize at the animal housing facility 
of the Slovak Medical University (Bratislava, Slovakia) are 
presented. These data constitute the basis for future study 
designs, power analyses and study result assessments at 
this particular animal housing facility. The data refer to the 
six conventional varieties used in the five feeding studies 
(Table 2) and deliver useful information on the magnitude 
and variability of the measured parameters in male and 
female Wistar Han RCC rats being fed a diet containing 
33 % non-GM maize for 90 days.
The ANOVA assessing the homogeneity of the historical 
control data showed a clear study effect. Moreover, in the 
case of body weight development and clinical biochemistry 
parameters, the data measured for diets containing the same 
maize variety are clearly clustered according to the stud-
ies (Fig. 3). This underlines the importance of comparing 
treatment groups (test and control groups) within studies. 
In the case of future feeding trials to be performed at the 
animal housing facility of the Slovak Medical University, 
the historical control data will help in determining whether 
the values of individual parameters measured in maize-fed 
rats show deviations from the corresponding normal range 
for rats held at the above-mentioned institution.
When analysing the historical control data, no statis-
tically extreme values were excluded, in line with the 
approach in single study analyses where there were no 
technical reasons to do this. Consequently, the variability 
of some parameter values is high. In this context, the his-
torical control data showed a reduced variability in studies 
C, D and E compared to studies A and B, which contained 
more extreme values.
Evaluation of the toxicological relevance of statistically 
significant differences between control and test groups
Consistency of statistically significant differences
The methods to evaluate the consistency of statistically 
significant differences between control and test groups 
showed inconsistency both in the frequency of statisti-
cally significant differences and in the difference values. 
Statistically significant differences in one study were not 
reproduced in other studies, except in the following seven 
cases: (1) male, 33 % GMO—control, neutrophiles: study 
D and E; (2) female, 33 % GMO—control, WBC: study 
B and D; (3) female, 33 % GMO—control, LYM: study B 
and D; (4) female, 11 % GMO—control, ALT: study A and 
Table 6  continued
Parameter 11 % GMO–control 33 % GMO–control





















 Thymus [%] 0.011 0.018 0.020 −0.016 0.016 −0.001 0.028 0.007
 Pancreas [%] 0.017 −0.029 −0.024 0.008 0.017 −0.015 −0.016 0.014
 Uterus [%] 0.015 −0.012 0.030 −0.004 0.004 −0.012 0.019 −0.017
 Ovary (right) [%] 0.003 −0.001 0.001 −0.002 0.002 0.001 0.003 −0.002
 Ovary (left) [%] 0.002 −0.001 −0.001 −0.001 0.003 0.000 −0.001 0.000
 Brain [%] 0.003 −0.042 0.021 −0.002 0.022 −0.020 0.015 −0.012
Body weight values are not included, since the body weight development (not the week−by−week body weight) was analysed
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D; (5) female, 33 % GMO—control, ALT: study B and D; 
(6) female, 33 % GMO—control, AST: study B and D; (7) 
female, 11 % GMO—control, U: study B and D. Therefore, 
the great majority of the differences was only found in a 
single study, and the toxicological relevance of these sta-
tistically significant differences between control and test 
groups is questionable.
A higher percentage of statistically significant differ-
ences between rats fed the control diets and those fed the 
diets containing the MON810 maize was observed in the 
studies A and B than in the studies C, D and E. In this con-
text, it has to be pointed out that the GRACE project part-
ners did not find any evidence that this was due to major 
differences in the composition of the diets, to technical 
defects of the laboratory equipment used or to mistakes in 
the handling of the blood samples by the laboratory staff.
Comparison of the data sets from GM maize‑fed rats 
with the historical control data
About 80 % of the individual parameter measurements in 
the GM maize-fed groups were within the simplified equiv-
alence limits defined by the historical control data. If the 
parameter measurements fell outside the equivalence lim-
its, the corresponding differences were statistically signifi-
cant in 30 to 80 % of the cases.
The equivalence limits were calculated in a simplified 
way and had to be based on study-internal data; therefore, 
they only are rough estimates. A more refined equiva-
lence testing procedure will be elaborated in the European 
Commission-funded project G-TwYST (GM Plants 2 Year 
Safety Testing, www.g-twyst.eu).
Assessment of the statistical power of the studies
The post hoc power analysis revealed a power between 
0.50 and 0.85 to detect an effect size of one SD in stud-
ies designed according to international guidelines (EFSA 
2011b; OECD 1998, 2009) with samples sizes per group 
and sex of 10, 16 or 20, respectively (the experimental unit 
is the cage with two animals, i.e. 5, 8 or 10 cages á 2 ani-
mals). An effect size of one SD is not necessarily linked 
to a real toxicological relevant effect. The size of toxico-
logical relevance in absolute or SD units should be consid-
ered separately for each parameter by toxicologists, largely 
based on previous experience. Therefore, based on the his-
torical background data of the animal housing facility and 
its associated laboratories at the Slovak Medical University, 
the corresponding absolute effect sizes (in original units) 
were calculated (Table 9). They will constitute the basis for 
future study designs and power analyses. This is why they 
























































































































































































































































































































































































































































































2004 Arch Toxicol (2017) 91:1977–2006
1 3
Table 9  Required effect sizes detectable by study designs with sample sizes of 5, 8 or 10 cages á 2 animals per group and sex, power = 0.8 and 
α = 0.05, based on historical control data
Parameter Male Female
One SD n = 5×2 n = 8×2 n = 10 × 2 One SD n = 5×2 n = 8 × 2 n = 10 × 2
Body weight
 Week 0 [g] 6.5 7.9 6.0 5.3 6.4 7.8 5.9 5.2
 Week 1 [g] 7.8 9.5 7.2 6.4 7.1 8.7 6.5 5.8
 Week 2 [g] 9.1 11.1 8.4 7.5 8.7 10.6 8.0 7.1
 Week 3 [g] 11.9 14.5 10.9 9.8 10.8 13.2 9.9 8.9
 Week 4 [g] 14.9 18.2 13.7 12.2 11.7 14.3 10.8 9.6
 Week 5 [g] 15.4 18.8 14.2 12.6 12.2 14.9 11.2 10.0
 Week 6 [g] 17.1 20.9 15.7 14.0 13.2 16.1 12.1 10.8
 Week 7 [g] 18.4 22.4 16.9 15.1 14.0 17.1 12.9 11.5
 Week 8 [g] 20.4 24.9 18.8 16.7 14.2 17.3 13.1 11.6
 Week 9 [g] 20.7 25.3 19.0 17.0 14.9 18.2 13.7 12.2
 Week 10 [g] 21.2 25.9 19.5 17.4 15.8 19.3 14.5 13.0
 Week 11 [g] 22.7 27.7 20.9 18.6 16.4 20.0 15.1 13.4
 Week 12 [g] 22.4 27.3 20.6 18.4 17.6 21.5 16.2 14.4
 Week 13 [g] 23.5 28.7 21.6 19.3 18.4 22.4 16.9 15.1
Hamematology
 WBC [103/nl] 2.88 3.51 2.65 2.36 2.07 2.53 1.90 1.70
 RBC [1064il] 0.40 0.49 0.37 0.33 0.29 0.35 0.27 0.24
 HGB [g/dl] 0.83 1.01 0.76 0.68 0.47 0.57 0.43 0.39
 HCT [%] 2.25 2.75 2.07 1.85 1.28 1.56 1.18 1.05
 MCV [fl] 1.04 1.27 0.96 0.85 1.15 1.40 1.06 0.94
 MCH [pg] 0.62 0.76 0.57 0.51 1.31 1.60 1.21 1.07
 MCHC [g/dl] 0.97 1.18 0.89 0.80 2.09 2.55 1.92 1.71
 PLT [103/iil] 159.5 194.6 146.7 130.8 135.9 165.7 125.0 111.4
 LYM [1 03/iil] 2.43 2.96 2.24 1.99 1.84 2.24 1.69 1.51
 Lymphocytes [%] 5.05 6.16 4.65 4.14 6.15 7.50 5.66 5.04
 Neutrophils [%] 4.91 5.99 4.52 4.03 5.75 7.02 5.29 4.72
 Monocytes [%] 1.34 1.63 1.23 1.10 0.86 1.05 0.79 0.71
 Eosinophils [%] 0.79 0.96 0.73 0.65 0.76 0.93 0.70 0.62
 Basophils [%] 0.00 0.00 0.00 0.00 0.09 0.11 0.08 0.07
Clinical biochemistry
 ALP [ukat/l] 0.26 0.32 0.24 0.21 0.10 0.12 0.09 0.08
 ALT [ukat/l] 0.67 0.82 0.62 0.55 0.14 0.17 0.13 0.11
 AST [ukat/l] 0.79 0.96 0.73 0.65 0.84 1.02 0.77 0.69
 ALB [g/l] 3.17 3.87 2.92 2.60 4.38 5.34 4.03 3.59
 GLU [mmol/l] 2.14 2.61 1.97 1.75 1.29 1.57 1.19 1.06
 CREA [umol/l] 6.61 8.06 6.08 5.42 7.40 9.03 6.81 6.07
 TP [g/l] 2.80 3.42 2.58 2.30 5.47 6.67 5.03 4.49
 U [mmol/l] 0.75 0.92 0.69 0.62 0.72 0.88 0.66 0.59
 CHOL [mmol/l] 0.29 0.35 0.27 0.24 0.29 0.35 0.27 0.24
 Ca [mmol/l] 0.20 0.24 0.18 0.16 0.23 0.28 0.21 0.19
 Cl [mmol/l] 6.64 8.10 6.11 5.44 4.27 5.21 3.93 3.50
 K (mmol/l) 0.57 0.70 0.52 0.47 0.82 1.00 0.75 0.67
 Na [mmol/l] 9.94 12.13 9.14 8.15 5.37 6.55 4.94 4.40
 P [mmol/l] 0.52 0.63 0.48 0.43 0.41 0.50 0.38 0.34
 TRG [mmol/l] 0.24 0.29 0.22 0.20 0.16 0.20 0.15 0.13
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